美元预测：DXY保持近2年高点，因美联储暗示2025年的降息减少。DXY本周上涨0.81%，因美联储暗示2025年降息减少，国债收益率攀升，通胀担忧持续存在。

US Dollar Forecast: DXY Holds Firm Near 2-Year High as Fed Signals Fewer 2025 Cuts.DXY rises 0.81% for the week as the Fed signals fewer 2025 rate cuts, Treasury yields climb, and inflation concerns persist.

在纽约，道琼斯指数周五上涨510点，涨幅1.21%。涨幅最大的是英伟达（2.46%）、联合健康（2.37%）和高盛（2.17%）。

In New York, the Dow Jones Index went up by 510 points or 1.21 percent on Friday. Top gainers were Nvidia (2.46%), UnitedHealth (2.37%) and Goldman Sachs (2.17%).

美国股市在今年最后三个转折日反弹，标准普尔500指数上涨1%，纳斯达克指数上涨0.8%，道琼斯指数上涨497点。此前通胀数据低于预期，11月个人消费支出指数同比增长2.4%，略低于预期。这有助于缓解美联储预测2025年降息减少引发的市场担忧。政府关门的威胁和关税威胁带来的全球市场压力也打压了市场情绪。诺和诺德（Novo Nordisk）的新型肥胖药物在测试中没有达到目标，导致这家制药巨头的不良反应（ADR）暴跌17.7%，医疗保健行业成为人们关注的焦点。反过来，竞争对手礼来公司的股价上涨了1.4%。考虑到本周，三大股指均下跌2.3%，道琼斯指数创下2023年以来最糟糕的一周。

US stocks bounced back on the last triple witching day of the year, with the S&P 500 up 1%, the Nasdaq rising 0.8% while the Dow gained 497 points. The rally followed cooler-than-expected inflation data, with November’s PCE index showing a 2.4% year-over-year increase, slightly below expectations. This helped alleviate market concerns sparked by the Federal Reserve’s forecast of fewer rate cuts in 2025. Sentiment was also weighed down by the threat of a government shutdown and global market pressure from tariff threats. The healthcare sector took the spotlight after Novo Nordisk’s new obesity drug missed targets in its test, driving the pharmaceutical giant’s ADRs to plunge 17.7%. In turn, equities for competitor Eli Lilly gained 1.4%. Considering the week, all the three major averages sank 2.3% with the Dow booked its worst week since 2023.

美国股市从早盘下跌中恢复，周五走高，因为市场重新考虑了美联储明年加息减少可能对企业回报的影响。三大股指均从1%的跌幅回升至1.5%的高位，与美国国债的大幅反弹同步。这一跳跃标志着本周早些时候股市抛售的逆转，此前联邦公开市场委员会成员预计央行明年将减少降息，反映出对鹰派信号的过度反应。在11月核心个人消费支出价格指数（美联储首选的潜在通胀指标）的涨幅低于预期后，人们押注美联储可能仍会降低政策限制，这进一步支撑了反弹。诺和诺德（Novo Nordisk）的新型肥胖药物在测试中没有达到目标，导致这家制药巨头的不良反应（ADR）暴跌20%以上，医疗保健行业成为人们关注的焦点。反过来，竞争对手礼来公司的股价飙升了5%。

US stocks recovered from early losses to trade firmly higher on Friday as markets reconsidered the impact that fewer rate hikes by the Federal Reserve next year may have on corporate returns. All three major indices recovered from 1% losses to hover 1.5% higher, tracking the sharp rebound for Treasury securities. The jump marked a reversal from the equity selloff earlier in the week after FOMC members projected fewer rate cuts by the central bank next year, reflecting an overreaction to the hawkish signals. The rebound was further supported by bets that the Fed may still make policy less restrictive after a softer-than-expected increase in the core PCE price index during November, the Fed’s preferred gauge of underlying inflation. The healthcare sector took the spotlight after Novo Nordisk’s new obesity drug missed targets in its test, driving the pharmaceutical giant’s ADRs to plunge over 20%. In turn, equities for competitor Eli Lilly surged 5%.